CN Patent

CN117379370A — 用于口服给药的依达拉奉混悬剂

Assigned to Tanabe Pharma Corp · Expires 2024-01-12 · 2y expired

What this patent protects

本申请涉及一种用于口服给药的依达拉奉混悬剂，该依达拉奉混悬剂包含依达拉奉颗粒、分散剂和水；其中(i)所述分散剂是显示1％或更高的透射散射光强度的分散剂；(ii)所述分散剂是显示80度或更小的接触角的分散剂；或者(iii)所述分散剂是选自聚乙烯醇、甲基纤维素、羟丙甲纤维素、蔗糖脂肪酸酯和聚山梨醇酯中的一种或多种。

USPTO Abstract

本申请涉及一种用于口服给药的依达拉奉混悬剂，该依达拉奉混悬剂包含依达拉奉颗粒、分散剂和水；其中(i)所述分散剂是显示1％或更高的透射散射光强度的分散剂；(ii)所述分散剂是显示80度或更小的接触角的分散剂；或者(iii)所述分散剂是选自聚乙烯醇、甲基纤维素、羟丙甲纤维素、蔗糖脂肪酸酯和聚山梨醇酯中的一种或多种。

Drugs covered by this patent

Patent Metadata

Patent number
CN117379370A
Jurisdiction
CN
Classification
—
Expires
2024-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.